Successful Clearance of Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia with Daptomycin, Linezolid, and Meropenem Salvage Therapy

Abstract EN

Staphylococcus aureus is one of the most virulent Gram-positive organisms responsible for a multitude of infections, including bacteremia.

Methicillin-resistant Staphylococcus aureus (MRSA) is of special concern in patients with bacteremia.

Due to its associated poor clinical outcomes, morbidity, and mortality, the superlative salvage regimen for persistent MRSA bacteremia remains uncertain.

An 85-year-old white female presented with persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia.

Empiric antibiotic therapy with linezolid was initiated prior to blood culture results.

Once MRSA bacteremia was confirmed, alternative antibiotic therapy with daptomycin was initiated.

Blood cultures remained positive for MRSA despite three days of daptomycin therapy after which ceftaroline was added to the antibiotic regimen.

Blood cultures remained positive for MRSA despite seven days of combination therapy with daptomycin and ceftaroline.

Salvage therapy was then initiated with daptomycin, linezolid, and meropenem.

One day following initiation of salvage therapy, blood cultures revealed no bacterial growth for the remainder of the length of stay.

This report supports the effectiveness of salvage therapy consisting of daptomycin, linezolid, and meropenem in patients with persistent MRSA bacteremia.